Fmr LLC Trims Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

FMR LLC cut its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,078,746 shares of the company's stock after selling 49,698 shares during the period. FMR LLC owned 10.62% of Structure Therapeutics worth $164,856,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in GPCR. Principal Financial Group Inc. lifted its stake in shares of Structure Therapeutics by 230.0% in the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock valued at $23,936,000 after purchasing an additional 380,115 shares during the last quarter. Handelsbanken Fonder AB purchased a new stake in Structure Therapeutics in the 4th quarter valued at about $4,475,000. CCG Wealth Management LLC acquired a new position in Structure Therapeutics in the fourth quarter valued at about $4,068,000. Exome Asset Management LLC purchased a new position in Structure Therapeutics during the third quarter worth about $5,274,000. Finally, Candriam S.C.A. increased its position in shares of Structure Therapeutics by 59.6% during the fourth quarter. Candriam S.C.A. now owns 215,421 shares of the company's stock valued at $5,842,000 after acquiring an additional 80,421 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GPCR has been the topic of several recent analyst reports. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $81.29.

Remove Ads

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded down $0.05 during trading hours on Tuesday, reaching $18.90. 884,831 shares of the company were exchanged, compared to its average volume of 874,475. The firm has a market cap of $1.08 billion, a PE ratio of -25.54 and a beta of -1.35. Structure Therapeutics Inc. has a 1 year low of $13.22 and a 1 year high of $62.74. The stock's fifty day moving average is $20.52 and its 200 day moving average is $28.88.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Research analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.